FDA-approved Bones & muscles

Zilucoplan

Zilucoplan is a complement C5 inhibitor peptide. It is filed in this library under bones & muscles, a navigation topic rather than a statement of where it acts. As a regulatory matter it has at least one product approved by the FDA.

Regulatory status

Zilucoplan has an FDA-approved product on the U.S. market, marketed as Zilbrysq under application NDA216834.

The current label is held by UCB, Inc.

From the FDA label

What Zilucoplan is approved to treat

is indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.Quoted from the FDA-approved prescribing information

Boxed warning

The most serious warning on its label

WARNING: SERIOUS MENINGOCOCCAL INFECTIONS ZILBRYSQ, a complement inhibitor, increases the risk of serious infections caused by Neisseria meningitidis [see Warnings and Precautions ]. Life-threatening and fatal meningococcal infections have occurred in patients treated with complement inhibitors. These infections may become rapidly life-threatening or fatal if not recognized and treated early. Complete or update vaccination for meningococcal bacteria (for serogroups A, C, W, Y, and B) at least 2 weeks prior to the first dose of ZILBRYSQ, unless the risks of delaying therapy outweigh the risk of developing a serious infection. Comply with the most current Advisory Committee on Immunization PrQuoted from the FDA-approved prescribing information

The evidence

What has actually been published

One source on Zilucoplan, resolved to its journal of record. The title is listed so you can judge the evidence rather than take a summary on trust.

Nearby

Other peptides acting on bones & muscles

Not sure what applies to you?

A 60-second questionnaire, reviewed by a U.S.-licensed physician.

Find my protocol

Educational reference only. This page explains what has been published about Zilucoplan. It is not medical advice, it is not a diagnosis, and it carries no dosing information of any kind. OPTML does not offer or supply this compound unless a product page on this site says otherwise.

Treatment decisions are made by a licensed physician after an individual evaluation. Compounded preparations are not FDA-approved or evaluated by the FDA for safety, effectiveness, or quality. Individual results vary.

All 150 peptides